Avant Immunotherapeutics is merging with Celldex Therapeutics in a stock deal valued at $115 million. Celldex shareholders will wind up with a majority of the shares in the merged company, which will have development programs in vaccines and brain cancer immunotherapeutics. The merged company will also have a product on the market--the oral vaccine Rotarix. Celldex is privately held and Avant's shares closed at 55 cents on Friday.
- see this release
Related Articles:
Avant cuts staff, biodefense work in restructuring. Report
Avant celebrates endpoint failure for TP10. Report
Avant in deal to develop vaccines. Report
